Artemisinin Combination Therapy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Artemisinin Combination Therapy Market is segmented By Combination Therapy Type(Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Pyronaridine, Artesunate-Sulfadoxine-Pyrimethamine, Others), By End-User(Hospital, Clinics, Research Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global Artemisinin Combination Therapy Market reached US$ 547 million in 2023 and is expected to reach US$ 1,061 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.

Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of Plasmodium parasites in the blood of malaria patients. Artemisinin-Based Combination Therapy (ACT) is recognized for its cost-effectiveness, lower likelihood of adverse events, and widespread acceptance by patients and healthcare providers.

Scope

For know more Insights - Download Sample

Market Dynamics: Drivers & Restraints

High prevalence of malaria in developing in under developed countries 

Artemisinin combination therapy (ACT) is used for the treatment of plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries. 

There is a continuous and increasing need for effective therapies due to the high number of malaria cases in these areas. ACTs are essential in areas where malaria is endemic as the World Health Organization (WHO) presently recommends them as the first-line treatment for uncomplicated malaria. 

For instnace, according to the latest World malaria report in 2022, there were 249 million cases of malaria in 2022 compared to 244 million cases in 2021. Hence the high prevalence of malaria is driving the growth of this market.

Side effects associated with artemisinin combination therapy  

Side effects include nausea, vomiting, diarrhea, and dizziness are possible in particular patients. Patients may stop taking their medication or look for other forms of therapy as a result of these adverse effects, which can result in failure with the recommended treatment plan. 

For more details on this report – Request for Sample

Segment Analysis

The global artemisinin combination therapy market is segmented based on combination therapy type, end-user and region.

Artemether-Lumefantrine segment is expected to dominate the market share

Artemether-Lumefantrine is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The World Health Organization recommends that uncomplicated Plasmodium falciparum malaria should be treated with an artemisinin- lumefantrine combination therapy. This combination is used as the first-line drug for malaria in most countries. This factor drives the growth of the market in the forecast period.

The increasing clinical phase trials to create an innovative solution also acts as driving factor for the segment growth. 

For instance, on April 24, 2024, Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety. The trial was conducted in several African countries. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

Middle East and Africa  is expected to hold a significant position in the artemisinin combination therapy market share

The Middle East and Africa held the largest share in the artemisinin combination therapy market due to the presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries that are contributing to the growth of the market. 

For instance, the WHO African Region carries a disproportionately high share of the global malaria burden.

In 2022, the region accounted for about 94% of malaria cases (233 million) and 95% (580 000) of malaria deaths. Children under 5 accounted for about 80% of all malaria deaths in the Region.

Four African countries accounted for over half of all malaria deaths worldwide. It includes Nigeria (26.8%), the Democratic Republic of the Congo (12.3%), Uganda (5.1%) and Mozambique (4.2%). Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.

Market Segmentation

By Combination Therapy Type

• Artemether-Lumefantrine
• Artesunate-Amodiaquine
• Artesunate-Pyronaridine
• Artesunate-Sulfadoxine-Pyrimethamine
• Others

By End-User

• Hospital
• Clinics
• Research Centers 
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa  

Competitive Landscape

The major global players in the market include Novartis AG, Ajanta Pharma, Shinpoong Pharm.co., Ltd, Schwitz Biotech, Stravahealthcare, Enzymes Pharmaceuticals, Wellona Pharma, Saphnix Life Sciences, Centurion Laboratories Private Limited and SiNi Pharma Pvt Ltd among others.

Why Purchase the Report?

• To visualize the global artemisinin combination therapy market segmentation based on combination therapy type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of artemisinin combination therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global artemisinin combination therapy market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies